Regulatory 2023-08-31 | Ascelia Pharma significantly reduces organization to reach SPARKLE headline results PDF Report Presentation Webcast
Regulatory 2023-08-18 | Half-Year report 2023: Re-evaluation required after intra-reader inconsistency in scoring of images from phase 3 study SPARKLE PDF Report Presentation Webcast
Regulatory 2023-08-07 | Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE PDF Report Presentation Webcast
Regulatory 2023-06-16 | Ascelia Pharma presented Orviglance Hepatic Impairment Data and hosted a Q&A with liver imaging experts at the 2023 ESGAR Annual Meeting PDF Report Presentation Webcast
Regulatory 2023-05-11 | QUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completed PDF Report Presentation Webcast
Regulatory 2023-05-04 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2023 PDF Report Presentation Webcast
Regulatory 2023-04-13 | Correction: Ascelia Pharma publishes annual report for 2022 PDF Report Presentation Webcast
Regulatory 2023-04-13 | Ascelia Pharma publishes annual report for 2022 PDF Report Presentation Webcast
Regulatory 2023-04-03 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB PDF Report Presentation Webcast
Regulatory 2023-03-13 | Ascelia Pharma Mourns the Passing of Board Member René Spogárd PDF Report Presentation Webcast
Regulatory 2023-02-28 | Change in number of shares and votes in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2023-02-21 | Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program PDF Report Presentation Webcast
Regulatory 2023-02-10 | QUARTERLY REPORT Q4 2022: Orviglance phase 3 study, SPARKLE, expected to be completed in Q1 2023. PDF Report Presentation Webcast
Regulatory 2022-12-06 | New Strong Orviglance Data Support Successful SPARKLE Completion with Substantially Fewer Patients PDF Report Presentation Webcast
Regulatory 2022-12-02 | Nomination Committee appointed for AGM 2023 in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2022-11-04 | QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission PDF Report Presentation Webcast
Regulatory 2022-08-18 | Half-year report 2022: Strong results from Orviglance Food Effect Study PDF Report Presentation Webcast
Regulatory 2022-05-11 | Quarterly Report Q1 2022: Strong Orviglance support from healthcare professionals PDF Report Presentation Webcast
